Kelly D. Johnson, United States of America

Merck & Co., Inc. Center for Observational and Real World Evidence (CORE)

Poster Author Of 2 e-Posters

Online Abstracts Population Sciences - Epidemiology, Economics, and Mathematical Modelling D1 Epidemiology, Economics, and Mathematical Modelling
Online Abstracts Vaccines - Impact of Vaccine programs and Serotype Replacement C2 Impact of Vaccine programs and Serotype Replacement

Presenter Of 2 Presentations

ECONOMIC BURDEN OF PNEUMOCOCCAL DISEASE IN INDIVIDUALS AGED 15 YEARS AND OLDER IN SPAIN: AN APPROXIMATION BASED ON THE CONJUNTO MÍNIMO DE DATOS-HOSPITALIZACIÓN (CMBD-H) (ID 780)

Abstract

Background

Streptococcus pneumoniae is a major cause of morbidity and mortality worldwide, being the most common etiological pathogen of pneumonia, meningitis and bacteremia. This study assessed the healthcare resource utilization and costs associated with inpatient admissions for pneumonia and invasive pneumococcal disease (IPD) in individuals aged 15 years and older in Spain during 2015.

Methods

A retrospective, descriptive study was conducted using Conjunto Mínimo de Datos-Hospitalización (CMBD-H), a publicly available database provided by the Spanish Ministry of Health capturing approximately 90% of hospitalization episodes.

The economic burden of pneumococcal disease was calculated by multiplying the average cost associated with an inpatient admission for pneumonia or IPD by the number of each type of episode. Additionally, the length of stay (days of hospitalization) due to pneumococcal disease was estimated

Results

The aggregated annual economic burden of pneumococcal disease was 54.1 million euros ($60.1 million) These represented over 97,390 hospitalization days, 80% of which were associated with pneumococcal pneumonia. Pneumococcal meningitis has the highest average cost per episode, 10,706 euros ($11,904) followed by the average cost of a septicemia episode, 9,338 euros ($10,382).

Conclusions

These results demonstrate the substantial economic impact of pneumococcal disease on the Spanish National Health System.

Hide

BURDEN OF DISEASE ASSOCIATED WITH PNEUMONIA AND INVASIVE PNEUMOCOCCAL DISEASE (IPD) IN INDIVIDUALS AGED 15 YEARS AND ABOVE IN SPAIN (ID 774)

Abstract

Background

The available burden of disease (BoD) studies in pneumococcal disease in Spain are limited to analyzing data restricted to specific geographical regions. This study assessed the clinical burden associated with streptococcus pneumoniae in Spain.

Methods

A retrospective study was conducted using Conjunto Mínimo de Datos-Hospitalización (CMBD-H), a publicly available database provided by the Spanish Ministry of Health covering approximately 90% of hospitalization episodes.

The study population consisted of individuals aged 15 years and older who were hospitalized with a diagnosis of pneumonia, bacteremia and meningitis due to Streptococcus Pneumoniae in 2015.

Results

In 2015, the estimated burden of pneumococcal disease potentially avoidable through vaccination represented 10,274 inpatient admissions including 9,015 cases of pneumonia, 309 cases of meningitis and 950 cases of septicemia. Additionally, 867 deaths were registered during these hospitalization episodes. The information available in CMBD-H only captures individual hospitalization episodes and cannot capture per patient hospitalization, therefore it could be used as an approximation to estimate disease incidence, but not real incidence, which is a limitation of the study.

Conclusions

Pneumococcal disease still contributes to substantial morbidity and mortality among individuals aged 15 years and older in Spain.

Hide

Author Of 2 Presentations

BURDEN OF DISEASE ASSOCIATED WITH PNEUMONIA AND INVASIVE PNEUMOCOCCAL DISEASE (IPD) IN INDIVIDUALS AGED 15 YEARS AND ABOVE IN SPAIN (ID 774)

Abstract

Background

The available burden of disease (BoD) studies in pneumococcal disease in Spain are limited to analyzing data restricted to specific geographical regions. This study assessed the clinical burden associated with streptococcus pneumoniae in Spain.

Methods

A retrospective study was conducted using Conjunto Mínimo de Datos-Hospitalización (CMBD-H), a publicly available database provided by the Spanish Ministry of Health covering approximately 90% of hospitalization episodes.

The study population consisted of individuals aged 15 years and older who were hospitalized with a diagnosis of pneumonia, bacteremia and meningitis due to Streptococcus Pneumoniae in 2015.

Results

In 2015, the estimated burden of pneumococcal disease potentially avoidable through vaccination represented 10,274 inpatient admissions including 9,015 cases of pneumonia, 309 cases of meningitis and 950 cases of septicemia. Additionally, 867 deaths were registered during these hospitalization episodes. The information available in CMBD-H only captures individual hospitalization episodes and cannot capture per patient hospitalization, therefore it could be used as an approximation to estimate disease incidence, but not real incidence, which is a limitation of the study.

Conclusions

Pneumococcal disease still contributes to substantial morbidity and mortality among individuals aged 15 years and older in Spain.

Hide

ECONOMIC BURDEN OF PNEUMOCOCCAL DISEASE IN INDIVIDUALS AGED 15 YEARS AND OLDER IN SPAIN: AN APPROXIMATION BASED ON THE CONJUNTO MÍNIMO DE DATOS-HOSPITALIZACIÓN (CMBD-H) (ID 780)

Abstract

Background

Streptococcus pneumoniae is a major cause of morbidity and mortality worldwide, being the most common etiological pathogen of pneumonia, meningitis and bacteremia. This study assessed the healthcare resource utilization and costs associated with inpatient admissions for pneumonia and invasive pneumococcal disease (IPD) in individuals aged 15 years and older in Spain during 2015.

Methods

A retrospective, descriptive study was conducted using Conjunto Mínimo de Datos-Hospitalización (CMBD-H), a publicly available database provided by the Spanish Ministry of Health capturing approximately 90% of hospitalization episodes.

The economic burden of pneumococcal disease was calculated by multiplying the average cost associated with an inpatient admission for pneumonia or IPD by the number of each type of episode. Additionally, the length of stay (days of hospitalization) due to pneumococcal disease was estimated

Results

The aggregated annual economic burden of pneumococcal disease was 54.1 million euros ($60.1 million) These represented over 97,390 hospitalization days, 80% of which were associated with pneumococcal pneumonia. Pneumococcal meningitis has the highest average cost per episode, 10,706 euros ($11,904) followed by the average cost of a septicemia episode, 9,338 euros ($10,382).

Conclusions

These results demonstrate the substantial economic impact of pneumococcal disease on the Spanish National Health System.

Hide